KineMed's TM & PM Platform Creates Value

Society increasingly needs treatments for a host of chronic and devastating diseases, such as Alzheimer's disease, atherosclerosis, cancer, osteoarthritis, and chronic obstructive pulmonary disease. The pharmaceutical industry needs better ways to create and advance the drugs of the future to address these real and growing needs.

Simply scaling up the current R&D practices is not a viable solution to the overwhelming challenge. Clearly, substantial improvements to the effectiveness of pharma R&D are the real solution. Pharma faces high attrition of development phase compounds and must repeatedly make very costly decisions about whether or not and how to progress compounds "guided" by wisps of information. KineMed specializes in quickly and cost-effectively generating exactly the sorts of information that improve the odds of making the right choices at these key decision nodes. While the information is not pefect, it is of high quality and has clear implications for the eventual success or failure of a particular compound dosed in a defined regimen to individuals with defined disease characteristics. Having access to this enriched information early in clinical development markedly increases the chances of identifying and watering future "flowers" and plucking future "weeds". The impact of this improved decision making across a portfolio of opportunities is markedly better R&D success, measured as both the rate of launch of best-in-class medicines and as return on investment.